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claim date was designated as the index date. Continuous health plan enrollment 
12 months pre- and post-index date was required. Patients were assigned to four 
monotherapy AED cohorts based on drug class: sodium channel blockers (SCs), 
gamma-aminobutyric acid analogs (GABAs), synaptic vesicle protein 2A binding 
(SV2) and multiple mechanisms (MMs). Adherence was assessed using the propor-
tion of days covered (PDC) and persistence was defined as days to discontinua-
tion with an allowable treatment gap of 45 days without the index AED. Logistic 
and Cox proportional hazards models were used to compare the results among 
the cohorts. RESULTS: Patients in the SC cohort had significantly lower baseline 
Charlson Comorbidity Index scores (1.82), indicating that they were healthier than 
those in the GAMA (2.08, p< 0.001) and SV2 (2.46, p< 0.001) cohorts. Patients in the SC 
cohort were significantly less likely to have a baseline psychiatric disorder (37.6%) 
than those in the GABA (63.8%, p< 0.001) and MM (52.1%, p< 0.001) cohorts. Patients 
treated with GABAs (OR= 0.44, p< 0.001) and MMs (OR= 0.63, p< 0.001) were signifi-
cantly less likely to adhere to their medications (PDC < 80%) than those treated 
with SC. Furthermore, patients treated with GABAs (hazard ratio [HR]= 1.74; 95% 
confidence interval [CI]= 1.59-1.90) and MMs (HR= 1.18; 95% CI= 1.07-1.29) were more 
likely to discontinue treatment during the follow-up period compared to those in the 
SC cohort. CONCLUSIONS: Patients treated with Sodium channel blockers are more 
likely adhere to treatment and have lower discontinuation of AED monotherapy 
than those treated with GABAs and MMs.
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OBJECTIVES: This study examined the relationship between medication adherence 
and outcomes in multiple sclerosis (MS), where both concepts are more difficult to 
measure than in diseases like hypertension where most medications are taken orally 
and surrogate outcomes (e.g., blood pressure) are routinely collected. METHODS: 
MS patients age ≥ 18 years treated at Geisinger Clinic and taking an MS medication 
were surveyed three times, six months apart, to assess medication adherence and 
MS outcomes. Patients reported their doses taken in the past month (adherence), 
number of relapses, TQSM medication satisfaction score, and MSIS physical and 
psychological functional scores. Nonparametric bootstrap analyses were used to 
compare mean outcome scores among patients with and without missed doses. A 
sub-analysis on patients with Geisinger insurance claims was conducted to calcu-
late patient’s MS medication possession ratio (MPR) from 2004 to 2013 and compare 
this claim-based adherence measure with the other results. RESULTS: 306 patients 
completed 971 surveys. Most patients were white (99%), female (85%), ages 22 to 76 
years old (median 50 years). Median time since initial MS diagnosis was 11 years. 
Mean self-reported adherence was 90% (median= 100%, IQR= 92-100%). Most patients 
(80%) reported zero relapses. Patients with no missed doses had significantly higher 
medication satisfaction than those with missed doses (77.5 vs. 72.5, p= 0.0006) and 
better psychological function (32.7 vs. 37.7, p= 0.017). There were no significant dif-
ferences between groups in reported number of relapses or physical functional 
status. MPR could only be calculated for 95 patients (37 had claims but not enough 
to calculate MPR), was extremely high in this subgroup (mean 96%, median 98%) 
and did not show the same associations with patient outcomes. CONCLUSIONS: 
Medication adherence in the actively treated MS population is very high, whether 
measured by self-report or MPR. Patients with 100% adherence showed evidence of 
better medication satisfaction and psychological function than others.
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OBJECTIVES: Whole genome sequencing (WGS) can be used to predict future dis-
ease risk or inform treatment. Current guidelines suggest only reporting variants 
that are clinically actionable. Reporting incidental or non-actionable findings could 
generate anxiety and unnecessary medical tests, but patients could miss valu-
able information if not reported. Over-treatment may occur by acting on findings 
prematurely, potentially causing harm and unnecessary resource use. We measure 
the value of WGS information using contingent valuation methods. METHODS: An 
online pilot survey (n= 26 adults from US general population) was used to evaluate 
willingness to pay for a basic WGS report (recommended by guidelines), and genetic 
information excluded from the basic report (non-actionable findings) to inform a 
national survey. Respondents were initially asked whether they would purchase a 
basic WGS report for a specified dollar amount. A follow-up question increased or 
decreased cost of the report based on the initial response. Responses were used 
to identify ranges of willingness to pay for a basic report for each respondent. The 
same steps were followed to identify ranges for respondents’ willingness to pay 
for information excluded from the WGS report. The initial costs in the questions 
were randomized across respondents. RESULTS: 42% of respondents (n= 11) were 
not willing to pay anything for the basic report, and no respondent was willing to 
pay more than $1000 for the basic report. Most respondents (n= 17, 65%) were not 
willing to pay anything for non-actionable genetic information, and only one person 
reported being willing to pay more than $400 for this information. CONCLUSIONS: 
A large number of participants perceived that genetic information can be harmful, 
as shown by respondents’ lack of interest in this information even if it were free. 
Our findings also suggest that respondents were willing to pay more for actionable 
genetic information than for non-actionable findings.
this study demonstrate, for the first time, the high resource utilization and financial 
burden experienced by sIBM patients in the USA. Further data collection of this 
type is needed to better understand the true economic burden of sIBM not only 
in US but globally.
Neurological DisorDers – Patient-reported outcomes & Patient Preference 
studies
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OBJECTIVES: Describe medication utilization patterns of migraine prophylactics 
in commercially insured patients. METHODS: Adult migraineurs (ICD-9 code 346.
XX) newly initiating migraine prophylactics (no claims for 12 months before first 
(index) prophylactic prescription) between January 2007 and March 2013 were identi-
fied from the OptumInsight employer claims database and followed for 6 months. 
Prophylactics included antiepileptics (topiramate, divalproex, valproic acid), beta-
blockers (propranolol, timolol), antidepressants (amitriptyline) and onabotulinum-
toxinA. Continuous enrollment was required for 12 months pre-index and 6 months 
post-index. To increase the specificity of migraine prophylactics, patients with prior 
diagnoses for conditions for which their prescribed prophylactics were also indi-
cated (i.e., epilepsy for antiepileptics, hypertension/congestive heart failure for beta-
blockers, and depression for amitriptyline) were excluded. Outcomes of interest were 
medication adherence (medication possession ratio [MPR]), discontinuation (> 30-day 
gap between prescriptions), and switching patterns. Time to discontinuation of initial 
prophylactic was described using Kaplan-Meier curves. RESULTS: 19,881 patients 
initiated prophylactic treatment with 12,136 (61%), 3,037 (15%), 4,163 (21%), and 545 
(3%) patients initiating antiepileptics, beta-blockers, amitriptyline, and onabotuli-
numtoxinA, respectively. Mean (SD) MPR for any prophylactic was 0.49 (0.31) (0.34 
(0.27)—valproic acid to 0.67 (0.22)—onabotulinumtoxinA) with a mean (SD) of 89.2 
(56.7) days on treatment over 6 months. Discontinuation rates were high ranging from 
74% (topiramate and onabotulinumtoxinA) to 90% (valproic acid). Switching rates 
ranged from 6% (topiramate) to 20% (valproic acid). Between 46% (topiramate) and 
68% (timolol) patients discontinued treatment after the first prescription, and median 
days to discontinuation of initial treatment ranged from 30 (valproic acid, divalproex, 
timolol, amitriptyline) to 84 days (onabotulinumtoxinA). CONCLUSIONS: Adherence 
to migraine prophylactic medications was poor with about 50% of patients discontinu-
ing after their first prescription and over 75% discontinuing within 6 months. The large 
proportion of patients discontinuing after first prescription suggests further research 
is needed on reasons for discontinuation and better tolerated therapies.
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OBJECTIVES: To review the methods currently used to measure adherence to 
oral and injectable disease modifying therapies (DMTs) in multiple sclerosis (MS) 
patients. METHODS: A systematic literature search was conducted using PubMed, 
CINAHL, PsychINFO, and Cochrane Library to identify articles assessing adherence 
to DMTs. The publication time frame was from January 2004 to November 2014. 
Studies were included if they focused on at least one U.S. FDA-approved injectable 
or oral DMT, assessed DMT adherence as either a primary or secondary outcome, 
reported DMT adherence rate(s), and included details of the method(s) used to 
calculate adherence level or proportion of adherers/non-adherers. RESULTS: A 
total of 36 studies met inclusion criteria. The majority (63.9%) of studies were con-
ducted in the U.S. All studies assessed adherence to at least one injectable DMT, 
while two studies also included an oral DMT. Twenty-two studies used a cross-
sectional, randomized controlled, or prospective observational study design. Among 
these studies, Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ), 
Medication Event Monitoring System (MEMS), adherence diary, self-reported sur-
vey items (designed specifically for respective study), Morisky 4-item medication 
adherence scale (MMAS-4), and self-reported missed dose ratios were used to assess 
adherence. Fourteen studies employed a retrospective design, using medication 
possession ratios (MPRs) and proportion of days covered (PDC) to assess adher-
ence. Although some of the measures (e.g., MEMS, MMAS-4, MPR, PDC) are well 
established, several of the self-reported items lack any evidence of reliability and 
validity. CONCLUSIONS: A plethora of methods have been used to assess DMT 
adherence, and each has its own unique advantage and disadvantage. The wide 
array of measurement methods and adherence definitions makes it difficult to 
compare adherence rates across studies.
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OBJECTIVES: To evaluate patient adherence and persistence to anti-epileptic drug 
(AED) monotherapy. METHODS: Adult patients (age> 18 years) with ≥ 2 epilepsy 
diagnosis claims (ICD-9-CM:345) or one epilepsy diagnosis claim and one claim for 
other convulsion (ICD-9-CM: 780.39) were selected from the U.S. Veterans Health 
Administration database (01OCT2008-30SEPT2013). Patients were required to 
have ≥ 1 AED prescription post-epilepsy diagnosis, and the first AED prescription 
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scored on a 0 (no difficulty) to 10 (unable to do) numerical rating scale. sIFA items 
are aligned with the functional impact of sIBM described in the literature/expert 
review and identified as relevant and important to sIBM patients. The draft concep-
tual framework includes items related to upper extremity, lower extremity, general 
function and swallowing. Cognitive testing of paper and ePRO versions support 
the use of this tool in a broad functional range of sIBM patients. CONCLUSIONS: 
The sIFA is the first content valid tool developed specifically for use in the func-
tional assessment of treatment benefit in sIBM patients aligned with the FDA PRO 
Guidance. Psychometric evaluation is underway.
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OBJECTIVES: To identify and review the suitability of cystic fibrosis (CF)-specific 
clinical outcome assessments (COAs) for clinical trial assessment of novel CF thera-
pies and to support product labelling. METHODS: CF-specific COAs were identified 
through an in-depth literature search using pre-defined search terms and via clini-
caltrials.gov. COA utilization in CF clinical trials and previous success in supporting 
product labelling was also explored. In line with best-practice, conceptual coverage 
of identified COAs was assessed by mapping items to a patient-centered conceptual 
model of CF symptoms and impacts. COAs with the most comprehensive conceptual 
coverage were further evaluated for content validity, psychometric properties and 
feasibility of use. RESULTS: Nine CF-specific COAs were identified; Cystic Fibrosis 
Questionnaire-Revised (CFQ-R) [pediatric 6-11/12-13 years, 14+ years and parent-
report 6-13 years] and Cystic Fibrosis Respiratory Symptom Diary (CFRSD) were 
selected for in-depth review. CFQ-R 14+ provided the most comprehensive concep-
tual coverage, assessing 52% of patient-centered symptom concepts and 50% impact 
concepts. Pediatric and parent-reported versions of CFQ-R assessed fewer concepts. 
All versions of CFQ-R have acceptable psychometric properties and are linguistically 
validated in > 30 languages. CFQ-R has also supported previous EMA and FDA label 
claims for respiratory symptoms. Limitations include the acceptability of a 2-week 
recall period and inconsistencies in concepts measured across pediatric and adult 
versions. CFRSD provides a comprehensive assessment of 83% of acute respiratory 
symptoms and 32% of acute impacts and is currently under evaluation for FDA Drug 
Development Tool qualification by FDA. The respiratory symptom score has excel-
lent psychometric properties; impact items are yet to be validated. CONCLUSIONS: 
Although 9 CF-specific COAs were identified in this study, only the CFQ-R measures 
and CFRSD appear potentially suitable for assessment of CF-related symptoms and 
impacts in CF clinical trials. Further data relating to content validity of CFQ-R may 
be required to support future labelling approvals.
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OBJECTIVES: The 39-item Parkinson’s Disease Questionnaire (PDQ-39) is the most 
thoroughly validated and extensively used self-report measure for the assessment 
of health-related quality of life in people with Parkinson’s (PwP). The measure has 
been shown to possess sound psychometric properties and its use is widely recom-
mended. Given the extent of its use and increasing emphasis on electronic data 
capture, a web based version of the PDQ-39, the ePDQ, has been developed. The aim 
here is to present reliability and validity data that confirm the psychometric quality 
of the ePDQ. METHODS: Recruitment of participants was undertaken with the sup-
port of Parkinson’s UK. Participants were emailed a unique link to an online survey 
containing the ePDQ and demographic questions. RESULTS: A total of 118 PwP (66 
males, 52 females) fully completed the ePDQ, a response rate of 91.4%. The mean age 
was 63.48 years, mean disease duration 5.73 years and mean age at diagnosis 57.69 
years. Score reliability was assessed by item-total correlations which ranged from 
0.34 to 0.90. Cronbach’s alpha was calculated at between 0.64 and 0.95 for the eight 
domains of the ePDQ. Construct validity was assessed by comparing group means 
for disease duration and gender and all previously hypothesised differences were 
confirmed. Furthermore, a higher order factor analysis confirmed the appropriate-
ness of calculating a summary score index. CONCLUSIONS: Data indicates that the 
ePDQ possesses appropriate levels of reliability and validity and largely mirrors the 
psychometric properties of the paper-based version.
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OBJECTIVES: Over-the-counter (OTC) sleep aids are widely self-administered and 
are generally safe, but their primary ingredients (diphenhydramine and doxylamine 
(DPH/DOX)) may pose risks, especially in older adults who may use these products 
outside of their label recommendations. This analysis characterizes the use of DPH/
DOX for sleep disturbances by age and sex in older American adults. METHODS: 
Data were taken from the 2013 US National Health and Wellness Survey (NHWS), a 
cross-sectional, internet-based, IRB-approved annual survey of adults (N= 75,000). 
Stratified sampling was used to represent the demographic make-up of the general 
population in age, sex, and ethnicity. Weights were applied using age, sex, eth-
nicity, and education to reflect the US population. Respondents reporting regular 
sleeplessness symptoms and insomnia/sleep difficulties (SD) were included in the 
analysis. Comparisons between sexes were made using chi-square tests for cat-
egorical variables and t-tests for continuous variables. RESULTS: Of the projected 
41.3 M (n= 16,500) adults age ≥ 65, 15% (3.8 M age 65-74; 2.6 M age 75+) reported 
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OBJECTIVES: Patients with rare genetic diseases often experience a diagnostic odys-
sey; no diagnosis or a delay in obtaining a diagnosis, due to lengthy diagnostic 
work-ups. Whole-exome sequencing (WES) can rapidly identify the mutation(s) 
responsible for rare, single-gene diseases. Before incorporating this new technology 
into clinical practice, we must understand the value of diagnostic information. We 
aimed to identify key attributes surrounding the value of a diagnosis to develop a 
discrete choice experiment (DCE) survey to estimate the value of WES diagnostic 
information to parents of children with rare diseases. METHODS: We used a multi-
phase, mixed-methods approach to identify key attributes and levels. We conducted 
a literature review to identify an extensive list of candidate attributes. We used 
results from focus groups with parents of children (n= 15) and adults (n= 8) with 
rare diseases to identify additional attributes. Candidate attributes were refined 
by consultation with research team members (including medical geneticists). The 
DCE survey was pre-tested in a sample of parents of children with rare diseases 
(n= 5) and attributes were further refined. RESULTS: The DCE included six attributes, 
each with four levels: type of diagnostic (genomic sequencing, other genetic testing, 
operative procedures, series of tests and procedures); chance of a diagnosis (1/10, 
4/10, 6/10, 9/10); negative impact of diagnostic test results (lifestyle restrictions, 
victim of discrimination, labeled by others, no impact); positive impact of diagnos-
tic test results (lead to therapy); out-of-pocket cost ($250, $1000, $5000, $10,000); 
time to obtain a diagnosis (6 months, 3 years, 5 years, 10 years). CONCLUSIONS: 
The survey will be administered to n= 300 parents of children with rare diseases 
(diagnosed and undiagnosed) to evaluate willingness-to-pay for: WES, a diagnosis, 
and a faster diagnosis.
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OBJECTIVES: To identify and appraise the reporting on psychometric properties of 
selected patient reported outcome measures (PROs) used in multiple sclerosis (MS) 
Phase IV trials, and to identify PROs potentially suitable for Phase IV use. METHODS: 
We systematically searched PubMed, Clinicaltrials.gov, and MS conferences from 
2009 onwards to identify PROs used in MS Phase IV trials. For further assessment, 
we selected PROs on key MS concepts: health-related quality of life (HRQoL), mood/
depression, fatigue, and cognition. These PROs were appraised in the context of the 
U.S Food and Drug Administration guidance for work reporting on psychometric 
properties (validity, reliability, and responsiveness). RESULTS: A total of 24 PROs on 
the selected concepts were identified from 30 studies. PROs were MS-specific for 7 
of 13 HRQoL, 1 of 7 mood/depression, and 1 of 4 fatigue measures. No study reported 
using PROs that independently measure cognition, although most HRQoL and 
fatigue PROs have a mental/cognition subcomponent. Modern psychometric analy-
ses were conducted on MS International Quality of Life Questionnaire (MusiQoL), 
MS Impact Scale-29 (MSIS-29), MS Neuropsychological Screening Questionnaire 
(MSNQ), Fatigue Severity Scale (FSS), and Modified Fatigue Impact Scale (MFIS). 
MS-specific HRQoL PROs were well-validated and are potentially useful in trial set-
tings, namely MusiQoL, MSIS-29 and Hamburg QoL Questionnaire MS (HAQUAMS). 
The MSNQ, measuring mood/depression, reported reliability and content validity 
but have unknown construct validity and responsiveness. Generic PROs for mood/
depression generally lacked information on psychometric performance in MS 
patients. Among PROs measuring fatigue, FSS and MFIS appeared most promising 
for trial use, but did not have content validity for MS patients. CONCLUSIONS: 
Of the identified PROs, only a few were well-validated. More work is warranted to 
assess the suitability of insufficiently validated PROs for use in MS trials. Also, since 
mental deficit is a key concept in MS, future Phase IV trials should consider using 
PROs measuring cognition.
PND48
a Novel Measure to assess self-rePorteD Physical fuNctioNiNg iN 
PatieNts With sPoraDic iNclusioN boDy Myositis (sibM)
DeMuro C.1, Lewis S.1, Pax Lowes L.2, Alfano L.2, Tseng B.3, Gnanasakthy A.1
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Nationwide Children’s Hospital, 
Columbus, OH, USA, 3Novartis Pharmaceuticals, Cambridge, MA, USA
OBJECTIVES: sIBM is a progressive idiopathic inflammatory myopathy characterized 
by atrophy and weakness of proximal and distal muscle groups with the knee exten-
sors and wrist/finger flexors frequently involved as well as dysphagic processes. 
Progressive weakness results in a loss of independence and the need for assistive 
devices and supportive care. While no pharmacological treatments for sIBM are 
currently marketed, clinical trials are underway. To assess the potential treatment 
benefit of new therapies and track clinical progression, a patient-reported measure 
(PROM) of physical function, the siBM Physical functioning assessment (sIFA), was 
developed. METHODS: The sIFA was rigorously developed in accordance with the 
FDA PRO Guidance. This included literature review, medical expert and direct patient 
input. A single-visit, observational study involving sequential concept elicitation 
and cognitive debriefing interviews was conducted. Standard qualitative analytical 
methods were employed to analyze interview data and generate and pilot-test ques-
tionnaire items. RESULTS: Twenty concept elicitation and 19 cognitive debriefing 
interviews were conducted as well as consultation with six sIBM expert physicians. 
sIBM patients (n= 39) varied in age (mean= 67; range 46-81), duration of diagnosis 
(1 – 18 years), and functional impairment. The resultant PROM consists of 11 items 
